SCHEMBL2900923

SCHEMBL2900923

COC(=O)c1ccc(C(=O)OC)c(N=C=S)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 17/20 0.53
ALDH1A1 P00352 13/20 0.53
HPGD P15428 5/20 0.53
HSD17B10 Q99714 4/20 0.53
GLA P06280 4/20 0.53
GAA P10253 4/20 0.53
MAPT P10636 3/20 0.53
ATM Q13315 3/20 0.53
CASP1 P29466 1/20 0.53
CASP7 P55210 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.47
CA1 P00915 2/20 0.45
CA2 P00918 2/20 0.45
CA12 O43570 1/20 0.45
CA7 P43166 1/20 0.45
XDH P47989 1/20 0.45
CA9 Q16790 1/20 0.45
CA14 Q9ULX7 1/20 0.45
LMNA P02545 3/20 0.43
L3MBTL1 Q9Y468 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4248903 0.87 KDM4E (0.56) KDM4EALDH1A1HPGDHSD17B10GLA
SCHEMBL3320428 0.84 CA1 (0.45) KDM4EALDH1A1HPGDHSD17B10GLA
SCHEMBL9222470 0.84 KDM4E (0.49) KDM4EALDH1A1HPGDHSD17B10GLA
SCHEMBL1302650 0.83 FFAR4 (0.42) KDM4EALDH1A1HPGDHSD17B10GLA
SCHEMBL6118516 0.83 MAPT (0.53) KDM4EALDH1A1HPGDHSD17B10GLA
SCHEMBL15989291 0.83 NR4A2 (0.44) KDM4EALDH1A1HPGDHSD17B10GLA
SCHEMBL7119247 0.81 CA1 (0.45) KDM4EALDH1A1HPGDHSD17B10GLA
SCHEMBL1968518 0.80 ALDH1A1 (0.47) KDM4EALDH1A1HPGDHSD17B10GLA
SCHEMBL17334515 0.80 CFTR (0.57) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL2901256 0.79 PDGFRB (0.37) KDM4EALDH1A1HPGDHSD17B10GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298324-A1 Prolyl Hydroxylase Inhibitors SMITH KLINE BEECHAM CORPORATION (US) 2010-11-25 US disclosed
US-20100298324-A1 Prolyl Hydroxylase Inhibitors SMITH KLINE BEECHAM CORPORATION (US) 2010-11-25 US disclosed
EP-2240178-A1 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-10-20 EP disclosed
WO-2010059549-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2010-05-27 WO disclosed
WO-2009086044-A1 PROLYL HYDROXYLASE INHIBITORS SMITH KLINE BEECHAM CORPORATION (US) 2009-07-09 WO disclosed
WO-2009086044-A1 PROLYL HYDROXYLASE INHIBITORS SMITH KLINE BEECHAM CORPORATION (US) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298324-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 KDM4E 206/4885ALDH1A1 204/4885HPGD 79/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.